下载掌阅APP，畅读海量书库
立即打开
BioNTech plans to return €2bn to shareholders through share buybacks and a special dividend following the commercial success of its Covid-19 vaccine, the company said on Wednesday.
BioNTech周三宣布拟通过股票回购和特别股息向股东返还20亿欧元，此前该公司的新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗取得商业成功。
The German biotech, which launched the first Covid-19 vaccine in partnership with Pfizer, said it would also boost research and development spending by 50 per cent to €1.4bn to €1.5bn, as it seeks to develop a new range of drugs based on mRNA technology.
与辉瑞（Pfizer）联手推出首款COVID-19疫苗的这家德国生物技术公司表示，它还将把研发支出增加50%，达到14亿至15亿欧元。该公司正致力于开发一系列基于mRNA技术的新药。
“To continue our industry leadership, we intend to build on our 2021 success and rapidly advance multiple programs, including our mRNA-based immunotherapies, cell therapies, and bi-specific antibodies,” said Ugur Sahin, BioNTech’s co-founder and chief executive.
“为了继续保持行业领先地位，我们打算在2021年成功的基础上再接再厉，快速推进多项计划，包括我们基于mRNA的免疫疗法、细胞疗法和双特异性抗体，”BioNTech联合创始人和首席执行官乌格·沙欣（Ugur Sahin）表示。